Abstract:INTRODUCTION:With the ongoing COVID-19 pandemic, a number of rare complications have been reported.We present a case of a rare neurological complication in a patient with a newly diagnosed COVID-19 infection.CASE PRESENTATION: A 64-year-old man with recently treated intraabdominal infection (antibiotics and drainage) presented to the Emergency Department (ED) with a 3-day history of fevers, intermittent right-sided flank pain, and urinary symptoms.He was found to have a complicated urinary tract infection (UTI) due to Klebsiella pneumoniae.He was started on intravenous antibiotics.He was tested positive for the SARS-CoV2 virus.On day 5, he developed progressive hypoxemia with bilateral infiltrates on the chest x-ray.Remdesivir and dexamethasone were initiated.Despite that, the patient developed further progression of respiratory failure requiring intubation.He then failed extubation.On exam, the patient was noted to have profound bilateral lower extremity weakness (motor strength: upper extremities -4/5 bilaterally; lower extremities -2/5), absent deep tendon reflexes.Magnetic resonance imaging (MRI) of the brain and spine did not show any abnormal lesions.Lumbar puncture showed an elevated protein (147 (15-40 mg/dL)) with absent cells in the cerebrospinal fluid (CSF) (albuminocytologic dissociation).He was diagnosed with Guillain-Barré syndrome (GBS).Therapeutic plasma exchange (TPE) was initiated (IVIG was not recommended given the potential risk of hypercoagulability).The patient completed 5 days of TPE.The patient noted some improvement in the strength of upper extremities.Unfortunately, the patient later developed a multiorgan failure with recurrent aspiration events and renal failure.The patient and his family decided to proceed with hospice. DISCUSSION: GBS is a heterogenous acute immune-mediated polyneuropathy commonly triggered by various viral infections.There have been several reports of SARS-CoV-2 infection triggering both primary and recurrent GBS.It is thought to be induced by the cross-reactivity of viral antigens with myelin.The diagnosis of GBS should be suspected in patients with progressive symmetric muscle weakness and absent deep tendon reflexes.Electrodiagnostic (not done in our patient) and CSF studies are usually done to confirm the diagnosis.Albuminocytologic dissociation (elevated protein with normal WBC count in the CSF) can be detected in most patients, especially if CSF is obtained after 7 days since the onset of symptoms.Supportive treatment with close monitoring of respiratory function is extremely important in affected patients.Disease-modifying therapies include the use of IVIG or TPE.CONCLUSIONS: With the myriad of publications related to SARS-CoV-2 infection, we continue to learn more about the culprit virus.We believe that healthcare workers should be aware of autoimmune complications of COVID-19 infection given the ongoing pandemic.

Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine

Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases

Case of Guillain-Barré syndrome following COVID-19 vaccine

Guillain-Barré Syndrome and Variants Following COVID-19 Vaccination: Report of 13 Cases

Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine

Guillain-Barre syndrome following COVID-19 vaccines: A scoping review

A Death for Guillain-Barrè Syndrome After Receiving a COVID-19 Vaccine: A Case Report

Guillain-Barré syndrome following COVID-19 vaccination: An updated systematic review of cases

Guillain–Barré syndrome post-SARS-CoV-2 vaccine: a systematic review and data analysis on its clinical, laboratory, electrophysiological, and radiological features

A Case of Guillain-Barré Syndrome Associated With COVID-19

Association of Guillain–Barré syndrome following COVID-19 vaccination

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Incidence of Guillain-Barré Syndrome (GBS) after COVID-19 Vaccination: a Systematic Review and Meta-Analysis

Experience of treatment in critical Guillain-Barre Syndrome case after COVID-19 vaccination

Guillain Barre syndrome associated with COVID-19 infection: A case report

Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination

Guillain–Barré Syndrome After COVID-19 Infection in Korea: A Case Series

COVID‐19‐associated Guillain‐Barre syndrome: Postinfectious alone or neuroinvasive too?

COVID-19 AND NEUROLOGICAL AUTOIMMUNITY: A CASE OF SARS-COV-2-INDUCED GUILLAIN-BARRÉ SYNDROME

COVID-19-Associated Autoimmune Disease: A Rare First Case Report of Acute Motor Axonal Neuropathy Variant of Guillain-Barre Syndrome in a Woman Patient in New York City

Case report: Rare Guillain-Barré syndrome variants and mild encephalitis/encephalopathy with a reversible splenial lesion as the para-infectious manifestations of SARS-CoV-2 infection